RT Journal Article
SR Electronic
T1 Serology assays used in SARS-CoV-2 seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.13.22280957
DO 10.1101/2022.10.13.22280957
A1 Ma, Xiaomeng
A1 Li, Zihan
A1 Whelan, Mairead
A1 Kim, Dayoung
A1 Cao, Christian
A1 Yanes-Lane, Mercedes
A1 Yan, Tingting
A1 Jaenisch, Thomas
A1 Chu, May
A1 Clifton, David A.
A1 Subissi, Lorenzo
A1 Bobrovitz, Niklas
A1 Arora, Rahul K.
YR 2022
UL http://medrxiv.org/content/early/2022/10/15/2022.10.13.22280957.abstract
AB Background Many SARS-CoV-2 serological assays were rapidly developed during the COVID-19 pandemic. However, differences in detection mechanism limit the comparability of assay outputs.Methods As part of the SeroTracker global living systematic review of SARS-CoV-2 seroprevalence studies, we collated serological assays used in serosurveys between January 1, 2020 and November 19, 2021. We mapped performance metrics to the manufacturer, third-party head-to-head, and independent group evaluations, comparing the assay performance data using a mixed-effect beta regression model.Results Among 1807 serosurveys, 192 distinctive commercial assays and 380 self-developed assays were identified. According to manufacturers, 28.6% of all commercial assays met WHO criteria for emergency use (sensitivity [Sn.] >= 90.0%, specificity [Sp.] >= 97.0%). Third-party and independent evaluations indicated that manufacturers overstated the Sn. of their assays by 5.4% and 2.8%, and Sp. by 6.3% and 1.2%. We found in simulations that inaccurate Sn. and Sp. can substantially bias seroprevalence estimates corrected for assay performance.Conclusions The Sn. and Sp. of the serological assay are not fixed properties, but varying features depending on testing population. To achieve precise population estimates and to ensure comparability, serosurveys should select assays with strong, independently validated performance and adjust seroprevalence estimates based on assured performance data.Competing Interest StatementR.K.A. reports consulting fees from the Bill and Melinda Gates Foundation Strategic Investment Fund, past employment with Health Canada, and equity in Alethea Medical, all outside the submitted work. D.A.C. reports consulting fees from Sensyne Health, Oxford University Innovation, and BioBeats, each outside the submitted work.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=183634 Funding StatementSeroTracker receives funding for SARS-CoV-2 seroprevalence study evidence synthesis from the Public Health Agency of Canada through the Canada COVID-19 Immunity Task Force, the World Health Organization Health Emergencies Programme, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. L.S. is employed by WHO; no others at WHO, and no other funders, had any role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results. This manuscript does not necessarily reflect the views of the World Health Organization or any other funder. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from seroprevalence studies and the serological assays used therein are available from: https://serotracker.com/en/Explore https://serotracker.com/en/Explore